Community post

Locus Biosciences announced the completion of a phase 1b trial of CRISPR-Cas3-enhanced phage targeting E. coli in urinary tract infections. The trial met all the endpoints, and represents the first randomized, placebo-controlled trial using recombinant phage therapy. The company is advancing into Phase 2 trials to prove the efficacy of recombinant phage in precisely removing specific bacteria from the human body without harming any other bacteria in a patient’s microbiome.